Volume 3, Issue 5, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

A COMPREHENSIVE REVIEW OF THE ANALYSIS OF THE PATHOPHYSIOLOGY, ORIGIN, AND THERAPEUTIC APPROACHES OF CEREBRAL EDEMA

Sania Hassan[*1], Faizan-e-Mustaffa[2], Eeman Ayesha[3], Afaf Nawaz[4], Huzafa Manzoor[5], Shumaila Ijaz[6], Sawera Khalil[7], Fatima Asghar[8], Sobia Rafiq[9], Muhammad Raza[10], Rimsha Asghar[11], Maliha Fatima[12]

[1,2,3,4,5,6,7,8,9,10,11,12]*Institute of Biological Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Punjab, Pakistan*

[*1]saniahassan02054@gmail.com

DOI: https://doi.org/10.5281/zenodo.16015685

Keywords
Blood Brain Barrier, Ionic, Cytotoxic, Vasogenic, Astrocytes, Ammonia

Article History
Received: 11 April, 2025
Accepted: 02 July, 2025
Published: 17 July, 2025

Corresponding Author: *
Sania Hassan

Abstract

Cerebral edema, or intracerebral edema, is a life-threatening complication of most neurological disorders and diseases, including tumours, infections, strokes, and traumas. In this review, discussion is about the fundamentals of cerebral edema, including its causes, symptoms, and treatment. Cytotoxic, ionic and vasogenic edema are the three primary types that are elaborately discussed. Anion imbalance and energy failure lead to cytotoxic edema, an intracellular bulge. Ionic edema results when sodium and water ions move into the extracellular space following cytotoxic edema but prior to the breakdown in the blood-brain barrier (BBB). The most prevalent type, vasogenic edema, is initiated by disruption in the blood-brain barrier that facilitates movement of water and plasma proteins into the interstitium of the brain. The review also briefly discusses the concomitant of the neurovascular unit in maintaining the stability of the blood-brain barrier, the role of astrocytes, and the significance of ammonia in cytotoxic edema. Developing focused and efficient therapies to enhance patient outcomes and lower illness and death from cerebral edema requires an understanding of the unique mechanisms underlying each kind of the disorder.

INTRODUCTION

The buildup of fluid in the interstitial space is a characteristic of edema that leading to swelling in tissues [1]. One kind of extracellular edema is interstitial edema, which occurs when fluid accumulates in the spaces between cells in tissues [2]. Increased hydrostatic capillary pressure (often observed in heart failure patients), decreased oncotic capillary pressure (often observed in patients with liver disorders, nephrotic syndromes, or malnutrition), increased capillary permeability (often observed in burn or inflammatory damage), or impaired lymphatic drainage (often caused by lymphedema from the removal of lymph nodes or parasitic infection) can all contribute to this fluid accumulation [3]. Cells becomes swollen due to fluid retention within them in a condition known as intracellular edema that is the result of hypoxia, cellular injury, disruption of ion gradient as seen in cytotoxic edema of brain.

Edema can present in different forms based on its distribution, severity, and underlying cause [4]. These forms include unilateral, bilateral, localized, and generalized edema. Unilateral Edema: Swelling limited to a single side of the body or a specific Appendage. Bilateral Edema: Symmetrical swelling affecting both sides of the body, often in the lower

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

extremities. Localized Edema: Swelling limited to a specific area, organ, or tissue**.** Generalized Edema: Widespread swelling throughout the body often associated with systemic conditions. Edema can occur in any body part, including the brain, lungs, and eyes, but it most commonly affects the legs and feet [5] Particular kind of brain swelling called cerebral edema result from shocks like trauma, stroke, tumors, infections, hypoxia, or metabolic abnormalities [6]. It is composed of blood vessels, neurons, and glial cells but is not a muscle. It often happens alongside conditions like traumatic brain injuries and strokes. When things like increased capillary permeability filter net fluid more easily, decreased plasma oncotic pressure, or increased capillary hydraulic pressure, edema results. The brain is part of the brain's nervous system (CNS), which also includes the cervical spine. The CNS regulates thinking, memory, emotion, motor skills, sensory perception, and autonomic functions like breathing and body temperature [7].



Figure 1: This diagram shows a side view of the human brain, pointing out how the gray matter, white matter, and ventricles are arranged.

The central nervous system contains both gray matter, which is made up of neuron somas, and white matter, which is made up of myelin-wrapped axons [8]. The brain has white matter underneath and gray matter on the outside, while the spinal cord is arranged in the opposite way. Gray matter analyzes information, while white matter disseminates it throughout the nervous system. Blood is delivered to the front and back of the brain by the carotid and vertebral arteries, respectively, and to the latter by the basilar artery.

Cerebral edema is a brain swelling that may occur from a various brain insults such as stroke, trauma, infections, tumors, abscess, hypoxia, and toxic or metabolic disturbances [9]. It commonly occurs in conditions like stroke and trauma-induced brain damage, which are leading causes of death and disability. The three main types of cerebral edema are vasogenic, ionic, and cytotoxic. Cell energy failure, which commonly happens in ischemia, results in malfunctioning ATP-dependent Na+/K+ pumps and cytotoxic cerebral edema. This concentration of Na+ inside the cell causes cells to inflate, which is followed by an influx of water and chloride [10]. This intracellular edema primarily affects gray matter but also affects white matter due to astrocyte involvement. Ionic cerebral edema, usually accompanying cytotoxic edema, involves water and sodium moving from capillaries into the brain's extracellular space without BBB disruption. This type of edema reflects an ion imbalance from cellular damage and often represents a transition phase from cytotoxic to vasogenic edema [11].

Vasogenic edema is the most ordinary type and it happens when the blood-brain barrier is damaged or does not work properly. Ions and proteins that leak into the extravascular space cause osmotic fluid to be drawn into the brain's interstitium, particularly in the white matter. Cognitive impairment is often caused by white matter displacement from increased vascular permeability, which is exacerbated approximately tumors by substances such as vascular

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

elastic growth factor (VEGF), glutamate, and leukotrienes. This process can be seen clearly in cases of peritumoral edema, where the buildup of fluid causes noticeable damage to the white matter [12]. Peripheral, pulmonary, and lymphedema are among the various forms of edema that exist in addition to cerebral edema (including its varieties). Swelling in the lower extremities, especially the legs and feet is known as peripheral edema, and it is frequently seen during healthy pregnancies. It develops because of a number of factors, including increased plasma volume, sodium retention, and mechanical vein compression during pregnancy. Vascular changes or issues with how the body handles fluids everywhere can

also lead to swelling in the limbs [13]. Increased pulmonary capillary hydrostatic pressure (cardiogenic) or damage to the alveolar-capillary barrier (non-cardiogenic) can result in pulmonary edema, which is an accumulation of fluid in the lungs [14].When the lymphatic system is compromised, fluid and protein return to the vascular system is disrupted, leading to interstitial fluid accumulation and lymphedema [13]. Lipedema is often mistaken for lymphedema, but it is actually caused by an unusual amount of fat building up under the skin. It mostly happens to young women and does not usually involve the feet.

Cerebral Edema

Brain edema, as defined by [15], is an expansion of brain volume caused by an abnormal accumulation of fluid, either locally or diffusely, within the brain parenchyma. Its division into vasogenic and cytotoxic edema was a consequence of the understanding that brain edema is linked with either intracellular or extracellular fluid accumulation. When the blood-brain barrier (BBB) is impeded, excess water and plasma proteins can be free the extracellular space, causing vasogenic edema. Cytotoxic edema, on the contrary, occurs when damaged brain cells take excess water, which results in intracellular swelling.

Table 1: Different classes of cerebral edema and their general mechanism of action along with harmful effects

Cytotoxic Edema	**Energy failure disrupts Na^+/K^+ pump** **Na^+, Cl^-, and water enter cells.** **Cells (neurons, astrocytes) swell**	**Affects gray & white matter.** **Worsens ischemia.** **Promotes ionic edema.**
Ionic Edema	Follows cytotoxic edema. Fluid moves into brain. BBB intact at first.	Swells brain with intact BBB. Draws water in Leads to Vasogenic edema if BBB breaks.
Vasogenic Edema	BBB breakdown. Plasma and water leak.	White matter swelling Cognitive issues. Worsens near tumors. Can cause hemorrhage.

Cytotoxic edema

Other terms used for cytotoxic edema are oncosis, cellular edema, and oncotic cell swelling. During this premorbid cell process, extracellular Na^+ and other cations flood neurons and astrocytes unregulated, mainly by way of cation channels, and build up intracellularly due to breakdown of energy-dependent extrusion systems. In an effort to maintain electrical neutrality, the entrance of cations then triggers the intrusion of anions. Combining these processes invites water influx and induces osmotic swelling of the cells, better described as cytotoxic edema. Central nervous system cytotoxic edema is typically accompanied by brain edema [16]. Even though cytotoxic edema itself does not produce brain swelling, it reduces the extracellular concentration of water, Na^+, and Cl^-, and this produces a recent incline for such cases ions the neurovascular interface capillary. The cytotoxic edema-induced gradient promotes the trans capillary

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

increase of ionic edema under the right changes in permeability of the capillaries [17].

Stroke and traumatic head injury are frequent etiologies of illness and death. Many clinical brain diseases may lead to cerebral edema. It is associated with two different pathophysiologic mechanisms, each with its own molecular and physiological antecedents: cytotoxic (cellular) edema of astrocytes and neurons, and transcapillary passage of Na^+ and other ions and water and serum macromolecules [16]. Approximately one-third of the volume of the brain consists of astrocytes, the most abundant glial cells of the central nervous system (CNS) [18]. For the purpose support the nervous system in homeostasis, these cells communicate with neural cells , myelin-producing glial cells , neuroimmune cells , and capillary lining cells [19]. To achieve homeostasis within the central nervous system, astrocytes regulate pH, manage K^+ spatial buffering, provide lactate to neurons, assist with the synthesis of ATP, create glutamate glutamine, produce glutathione in the neuron, provide Ca^{2+} homeostasis, regulate osmolytes, and recycle oxidized ascorbic acid [20]. Also, they mediate neurotransmission, support synaptogenesis, construct and sustain the blood-brain barrier (BBB), provide energy for neurons, govern metabolic processes, and control synaptic plasticity [19].

There are two major sorts of astrocytes: fibrous astrocytes with expansive processes (high GFAP expression), typically present in white matter, and protoplasmic astrocytes, typically present in gray matter. In addition, the cerebral cortex has another type of astrocyte, which consists of varicose projection astrocytes in the fifth and sixth layers and cortical interlaminar astrocytes in the first layer [21]. The hepatic organ is the major body part in ammonia cleansing. Periportal hepatocytes transform ammonia into less toxic urea, that is water-dissolvable and ready for kidney excretion. In addition, perivenous hepatocytes' glutamine synthetase (GS) catalyzes the combination of ammonia and glutamate (Glu) to form glutamine (Gln). Blood ammonia level increase is guarded against by liver function and ammonia detoxification [22]. Since the detoxification capacity of the liver is impaired by pathologic states like liver failure, cirrhosis, or portosystemic shunt, increased ammonia levels enter the blood and cause systemic hyperammonemia.

Through potassium channels and a diffusion process, ammonia reaches the brain [23], and various specific transporters, including ammonia transporters, aquaporin channels, inward-rectifying K^+ channels, K^+/Cl^- symporters, Na^+/K^+ ATPase, Na^+/H^+ ATPase antiporters, and Na^+/K^+ $/2Cl^-$ symporters [24]. Significantly, the brain take up more ammonia from the blood with liver failure and hyperammonemia [25],[26]. It is only astrocytes within the central nervous system that can detoxify ammonia. Ammonia and glutamate are transferred to glutamine by these cells across the action of the glutamine synthetase (GS) enzyme. They export glutamine into the blood or extracellular space, where it is taken up by pre- or post-synaptic neurons. The primary neuropathological characteristic in the brain of patients suffering from acute liver dysfunction (ALF) is astrocyte swelling [27][28].

SLC26A11 found to be the major Cl^- influx pathway responsible for cytotoxic Na^+ dependent neuronal swelling.

Cytotoxic brain edema, which is the leading cause of death following brain injury and cerebral infarction, is caused by over-swelling of the neurons. Researchers used fluorescent lifetime imaging to analyze the contributions of intracellular ionic changes in brain slices and found that intense Na^+ entry leads to a subsequent increase in intracellular Cl^-, which is required for neuronal swelling and death. By using pharmacological and siRNA-mediated knockdown screening, it was found that the ion exchanger SLC26A11 surprisingly functions as a voltage-gated Cl channel that is activated when neurons depolarize to membrane potentials lower than 20 mV. Inhibiting SLC26A11 activity results in a reduction of both neuronal swelling and cell death. Thus, cytotoxic neuronal edema is caused by sufficient Na^+ influx and depolarization, which are followed by Cl entry via SLC26A11. The ensuing NaCl buildup results in neuronal swelling and, ultimately, neuronal death. These findings open the door for the development of targeted treatments for brain edema and provide light on various facets of excitable cell volume control [29].

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Ionic edema

Cytotoxic edema acts as a catalyst for the formation of ionic edema, which refers to the influx of Na^+, Cl^-, and H_2O into the brain, resulting in swelling [17]. Ionic edema occurs despite an intact blood-brain barrier and results in increased brain volume due to tissue water accumulation. Hypoxia generates cytotoxic edema, and this in turn generates an osmotic pressure, which draws water out of the blood vessels into interstitial tissue within the brain to form ionic edema with greater ease. As more intracellular fluid is removed from the surrounding extracellular space, fluid within the interstitial space is regulated. The rectitude of the brain's protective barrier is compromised if the pathogenic conditions persist, resulting in the creation of permeability pores and the initiation of vasogenic edema. Further damage to the endothelium results in the enlargement of these permeability pores, allowing erythrocytes to infiltrate brain tissue, a process referred to as hemorrhagic transformation [30].

Vasogenic edema

In Vasogenic edema, the upset of the Blood-Brain Barrier (BBB) leads to permeability gaps in the endothelial layer, allowing plasma proteins, including IgG and albumin, along with water to seep into the brain's extracellular space. Unlike hemorrhage, structural integrity of capillaries is preserved in vasogenic edema to avoid the migration of red blood cells. " Therefore, a useful way to think of vasogenic edema is as a blood ultra-filtrate that is either cell-free or plasma-like [31, 32]. Unlike osmotic gradients linked to cytotoxic edema, hydrostatic pressures sustain vasogenic edema. Most diseases, such as neoplasms, infections, inflammations, ischemic episodes, and hypertension, can affect the Blood-Brain Barrier (BBB). Transcriptional changes in the neurovascular unit caused by acute central nervous system (CNS) injuries, such as cytotoxic edema, ultimately lead to the formation of "endothelial permeability pores" and the subsequent disruption of the blood-brain barrier [33, 34].

Neurovascular Unit and Blood Brain Barrier

A micro vascular system made up of arterioles, venules, and capillaries distributed throughout different parts of the central nervous system (CNS) defines the Blood-Brain Barrier (BBB), a semi-permeable structure, despite the term suggesting a rigid and inflexible architecture [35]. It controls the flow of chemicals, ions, and fluids between the bloodstream and the brain [36]. By guaranteeing a steady concentration of hormones, nutrients, and water, the Blood-Brain Barrier (BBB) contributes significantly to the preservation of a healthy environment within the cerebral parenchyma. Through the blood-brain barrier bacteria along with toxic and viral agents work to block entry into the brain tissue. The central nervous system experiences protection through structural and functional mechanisms of the BBB [35]. Medical professionals describe the Neurovascular Unit (NVU) as the precise network of brain-parenchymal cell interactions with neurons and microglia and pericytes and astrocytes elements of the blood-brain barrier. Positioned midway within the Neurovascular Unit the BBB emerges from endothelial cells arranged into a single uniform layer with tight junctions [37].

Platelet-activating factors, endothelin, superoxide radicals, and eicosanoids are some of the multiple substances released. These drugs have the ability to block blood flow, raise the permeability of the blood-brain barrier, and damage cells when present in too high doses. Adhesion junctions (AJs), tight junctions (TJs), and gap junctions (GJs) are instances of junctional protein complexes that interconnect endothelial cells at the molecular level; endothelial cells line the vascular lumen [38]. The basolateral membranes of endothelial cells feature adherens junctions. AJs comprise transmembrane glycoproteins called cadherins as well as cytoplasmic proteins including p120 and catenins. Members of the Armadillo protein family, cadherins link to the cytoskeleton of ECs using p120 and catenins. Development of blood vessels, blood-brain barrier stability, and the integrity of intercellular connections depend on VE-cadherin, sometimes known as vascular endothelial cadherin [38, 39].

The core of endothelial cells consists in tight junctions. Transmembrane proteins themselves as well as cytoplasmic proteins that assist to bind transmembrane proteins, such as junctional adhesion molecule (JAM), claudin, and occludin,

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

link to the cytoskeleton of endothelial cells (ECs). Transmembrane protein occludin determines the integrity of the BBB. Through tight junctions, occludin controls paracellular permeability of endothelial cells and limits small molecule flow across the blood-brain barrier [40]. By altering the BBB's permeability to molecules of a given size, Claudins help to build barriers [41]. Claudins especially stop paracellular ion flow, so producing a strong electrical resistance across the barrier. Mainly JAM-A but also JAM-B and JAM-C, the junctional adhesion molecules (JAMs) keep the barrier function of tight junctions between cells. These tight junction proteins can alter the effects they have on integrin levels, which would affect the migration of leukocytes into the brain especially in diseases-related conditions. Furthermore connected to these transmembrane tight junction proteins does the cytoskeleton, the internal support structure of the cell, which comprises of proteins including cingulin and the Zonula Occludens (ZO) family, comprise ZO-1, ZO-2, and ZO-3 [38, 39].



Fig 2: The Neurovascular Unit (NVU) and the BBB. (A) The NVU shown in a transverse section. The NVU theory emphasises the importance of close interactions among BBB components and brain parenchymal cells—including neurones, astrocytes, pericytes, and microglia. The BBM is located in the middle of the monolayer of endothelial cells connected by tight junctions that makes up the NVU. (B) Tight junctions (TJs) and adherens junctions (AJs) of the BBB.

Adjacent endothelial cells' membranes feature special protein structures known as gap junctions. They make strong cell connections and direct cell to cell communication possible, thus, they are indispensable. Because they are made of channels created by proteins known as connexins, these junctions let ions and tiny molecules pass between cells [38, 42]. TJ upset Mostly due to tight junction (TJ), vasogenic edema is typified by an increase in the paracellular permeability of the blood-brain barrier [37]. Thus, one must understand the pathogenic processes causing disturbance of TJ. Three separate phases of TJ's increasing dysfunction are protein disruption, protein displacement, and protein modification. By raising BBB permeability, every stage can contribute to the edema development [43].

Protein Alteration: Following ischemic brain damage, inflammatory factors and cytokines

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

including tumour necrosis factor-alpha, monocyte chemoattractant protein-1 (MCP-1/CCL2), chemokine, and interlukin-6 (IL-6) become activated. These drugs give TJ proteins phosphate groups, so enhancing BBB permeability [37, 40, 41, 44]. Protein Displacement: The blood-brain barrier (BBB) is also impacted by this. The structural integrity of the barrier may be jeopardized by endocytosis and actin polymerization. JAM-A exits the spaces between cells, but when endothelial cells are exposed to chemicals like CCL2 or events like a stroke, proteins like occludin and claudin-5 are pulled into the cell core [45-47]. Moreover, research shows that increased actin polymerization and stress fiber formation cause occludin and cadherin to migrate from the cell membrane into the internal actin cytoskeleton, further rupturing cell connections [37, 48].

Protein Breakdown: During this phase, the BBB sustains major damage, which increases paracellular leakage and peripheral immune cell infiltration. This phase is mostly regulated by matrix metalloproteinases. The levels of MMP-2 and MMP-9, two of the most studied MMPs, typically rise sharply after a stroke [49-51]. Following a stroke, tight junctions (TJs), particularly Claudin-5 and occludin, and the microvascular basal lamina deteriorate due to increased MMP-2 and MMP-9 levels [52]. By selectively inhibiting MMP-2/9, cerebral ischemic mice's edema volume and blood-brain barrier damage can be greatly decreased [53]. As a result, one of the main causes of cerebral edema after a stroke is the disintegration of TJs, which lowers the integrity of the BBB [37].

Stage of Tj Dysfunction	Phosphorylation of Tj Proteins	Endocytosis/Act In Polymerization	Mmp Degradation (Claudin-Moccludin
Protein Alteration	✓		
Protein Displacement		✓	
Protein Breakdown			✓

Table 2: Different stages of tumor junction dysfunction

Traumatic Brain Injury (TBI)

Any closed head injury, even mild traumatic brain injury, might result in neurological problems [54, 55]. Edema, which develops gradually and is essential to the pathophysiology of brain injury, is one of the most harmful side effects. Cytogenic edema from cellular swelling in mild to severe TBI follows vasogenic edema from blood-brain barrier (BBB) rupture, and then a combination of the two. The frequency and intensity of these occurrences depend on the extent of brain damage. Diffusion-weighted imaging can be used to calculate the apparent diffusion coefficient (ADC), which gauges the level of edema after brain trauma. ADC provides a quantitative evaluation of water mobility. Cellular swelling caused by an imbalance in osmotic pressure across the plasma membrane decreases ADC readings. However, variations in the blood-brain barrier's permeability allow water and other solutes to enter the interstitial space, which raises the extracellular volume and results in vasogenic edema, which is indicated by elevated ADC readings. Higher intracranial pressure and parenchymal swelling are the results of this increase in brain fluids [55].

Approaches in the Treatment of Cerebral Edema

In neurocritical care settings, cerebral edema poses a serious management challenge. Effective treatments may result from an understanding of the causes of cerebral edema [31]. Diseases that classically have been associated with cerebral edema often present in neurosurgical patients [56]. Encompassing traumatic brain injury (TBI), ischemic stroke, and intracerebral hemorrhage (ICH). Rapid development of cerebral edema can cause increased intracranial pressure (ICP), reduced cerebral blood flow, and ultimately, poor neurological outcomes [57]. In spite of the high incidence and severity of cerebral edema, current

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

treatments are often relatively non-specific and confident [58]. A major aim and key part of the present review, therefore, is to provide a summary of the recent development strategies for treating cerebral edema, to discuss the potential drawbacks of these treatments, and to attempt evaluating agents with promise in treating this difficult condition.

Current Treatment Approaches

Hyperosmolar Therapy: Hyperosmolar agents are very important in the treatment of brain swelling. There are two broad main choices: mannitol and hypertonic saline [59]. Mannitol: Mannitol, an osmotic diuretic, had been used since the 1960s. It formed an osmotic gradient across an intact BBB, drawing water into the intravascular space. Although it is successful in reducing cerebral edema, mannitol has several disadvantages [60]. It will rapidly expand intravascular volume, potentially causing pulmonary edema or heart failure in susceptible patients. Being a diuretic, it may also cause intravascular volume depletion, hypotension, and acute kidney injury by prolonged use [61]. Hypertonic Saline (HTS):HTS has been used as a common substitute for mannitol. It, like mannitol, creates an osmotic gradient but does not have a diuretic effect, rather adds intravascular volume. There is evidence that HTS is a better agent than mannitol for ICP management, especially in TBI patients [62]. But, once again, HTS is dangerous: it can cause metabolic derangements, volume overload and coagulopathy [63].The mannitol or HTS choice is thus dependent on the ailment and what is needed in that specific situation. Current Neurocritical Care Society recommendations suggest the use of HTS over mannitol for ICH-related edema, although these recommendations are made in the context of low evidence based [64]. Surgical Interventions: In instances of severe edema or refractory intracranial hypertension, surgical intervention is mandatory [65]. The aim is life-saving decompressive craniectomy in some carefully selected cases-the removal of part of the skull to allow the brain to expand. Such a procedure does carry a significant risk of infection and the requirement for later cranioplasty [59]. Other medical treatments: Although corticosteroids are very useful in reducing edema caused by brain tumors, they find little use in cerebral edema due to other causes [66]. Furosemide is sometimes used as an additional therapy with hyperosmolar therapy but usually not as a single therapy agent for the management of ICP [67, 68].



Fig 3: The figure compares treatment methods for managing brain swelling, including mannitol, hypertonic saline, surgical Intervention, and other treatments, highlighting their effectiveness and risks

Condition-Specific Approaches

The management of cerebral edema can vary depending on the underlying condition: Traumatic Brain Injury (TBI): Recent evidence shows that HTS

Volume 3, Issue 5, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

is now preferred over mannitol in the first treatment of high ICP or brain swelling in TBI [69]. Acute Ischemic Stroke: For ischemic stroke, HTS and mannitol are good choices for initiating treatment, but the evidence does not exist for one being better than the other for better brain recovery [70]. Subarachnoid Hemorrhage (SAH):Therefore, the best management of cerebral edema in SAH remains unclear. As of date, the data are insufficient to support targeting serum sodium concentrations at set intervals or definitively recommend HTS over other treatments [71] [57]. Liver Encephalopathy: In hepatic encephalopathy, HTS or mannitol may be used to control ICP or brain swelling. The decision in most cases would again depend on factors specific to the patient [72] [57].



Fig 4: Preferences for treating brain swelling depending on the particular ailment, such as hepatic encephalopathy, subarachnoid hemorrhage, acute ischemic stroke, or traumatic brain injury

Emerging Therapies

Recent advances in our understanding of cerebral edema pathophysiology brings about the development of more targeted therapies: SUR1-TRPM4 Channel Inhibition: Glyburide is a class of medication known as a sulfonylurea. It has been promising to inhibit SUR1-TRPM4 channels, which are implicated in fluid accumulation. It has proven to reduce brain swelling in animal models of stroke, head trauma, and intracerebral hemorrhage. Human clinical trials are underway to determine if it is useful in humans [73] [69]. Aquaporin-4 Regulation:Aquaporin-4 (AQP4) water channels are thought to play a critical role in the balance of water levels within the brain [74]. The latter might be achieved by directly blocking AQP4 or interfering with how it moves in and out of cell membranes; research into treatment possibilities has focused on how the activity of calmodulin might restrict the positioning of AQP4 within cells, thus reducing lump [75] [76]. Anti-inflammatory Agents:COX-2 inhibitors, such as celecoxib, may help control swelling and blood clots in ICH [69] [77]. This is promising but certainly calls for further studies regarding their effectiveness and safety in clinical environments [78]. Deferoxamine has demonstrated in ICH the ability to reduce swelling of the brain and to benefit outcomes from animal experiments. It is being explored in clinical trials for human use [79, 80].

Challenges and Future Directions

Our knowledge of cerebral edema is expanding, but there are still many challenges to be solved. Current treatments for edema usually concentrate on its

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

symptoms rather than its underlying causes [81, 82]. The development of therapies that target specific molecular pathways linked to the onset of edema is an important area for additional research. Combination therapies may be more successful because they address several facets of edema development and resolution [83] [84]. In addition, individualized therapy that takes into account the special underlying pathology as well as the patient's particular characteristics can enhance the efficacy of treatment [85, 86].

Conclusion

Concisely, cerebral edema has been classified as a pathological condition that largely influences neural functioning and prognostic outcomes. Vasogenic, ionic, and cytotoxic edema are some of the other significant forms of edema, with each having its unique pathophysiological processes. Surgery, hyperosmolar therapy, and molecular targeting are some of the present treatments available for cerebral edema; however, treating the primary cause of cerebral edema is still problematic. As research has advanced, it has expanded our knowledge of blood brain barrier, neurophysiological interaction, and mechanism of ionic transport thereby allowing for more complex measures such as Aquaporin-4 modulation and SUR1-TRPM4 blockage. Research needs to develop personalized specialized medical processes for decreasing cerebral edema while improving brain restoration mechanisms.

References

Besharat, S., et al., Peripheral edema: A common and persistent health problem for older Americans. Plos one, 2021. 16(12): p. e0260742.

Engel, J., et al., Edema related to treatment with psychotropic drugs. Journal of Neural Transmission, 2024. 131(3): p. 253-266.

Veluri, N. and K. Badwal, Idiopathic edema: a case report. Cureus, 2019. 11(7).

Trayes, K.P., et al., Edema: diagnosis and management. American family physician, 2013. 88(2): p. 102-110.

Greene, A. and P. Meskell, The impact of lower limb chronic oedema on patients' quality of life. International wound journal, 2017. 14(3): p. 561-568.

Gu, Y., et al., Cerebral edema after ischemic stroke: Pathophysiology and underlying mechanisms. Frontiers in neuroscience, 2022. 16: p. 988283.

Batista-García-Ramó, K. and C.I. Fernández-Verdecia, What we know about the brain structure–function relationship. Behavioral Sciences, 2018. 8(4): p. 39.

Herbet, G. and H. Duffau, Revisiting the functional anatomy of the human brain: toward a meta-networking theory of cerebral functions. Physiological Reviews, 2020. 100(3): p. 1181-1228.

Turner, R.E., et al., High-altitude cerebral edema: its own entity or end-stage acute mountain sickness? Journal of Applied Physiology, 2021. 131(1): p. 313-325.

Li, N., et al., Cytotoxic Edema and Adverse Clinical Outcomes in Patients with Intracerebral Hemorrhage. Neurocritical Care, 2023. 38(2): p. 414-421.

Campos, A., ionic cerebral edema. Radiopaedia, 2024.

Bilgin, E.Y., O. Unal, and N. Ciledag, Vasogenic Edema Pattern in Brain Metastasis. Age, 2022. 60(149): p. 51.

Cho, S. and J.E. Atwood, Peripheral edema. The American journal of medicine, 2002. 113(7): p. 580-586.

Murray, J., Pulmonary edema: pathophysiology and diagnosis. The International journal of tuberculosis and lung disease, 2011. 15(2): p. 155-160.

Jha, R.M., P.M. Kochanek, and J.M. Simard, Pathophysiology and treatment of cerebral edema in traumatic brain injury. Neuropharmacology, 2019. 145: p. 230-246.

Liang, D., et al., Cytotoxic edema: mechanisms of pathological cell swelling. Neurosurgical focus, 2007. 22(5): p. 1-9.

Simard, J.M., et al., Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. The Lancet Neurology, 2007. 6(3): p. 258-268.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Sofroniew, M.V. and H.V. Vinters, Astrocytes: biology and pathology. Acta neuropathologica, 2010. 119: p. 7-35.

Molofsky, A.V. and B. Deneen, Astrocyte development: a guide for the perplexed. Glia, 2015. 63(8): p. 1320-1329.

Allaman, I., M. Bélanger, and P.J. Magistretti, Astrocyte–neuron metabolic relationships: for better and for worse. Trends in neurosciences, 2011. 34(2): p. 76-87.

Tabata, H., Diverse subtypes of astrocytes and their development during corticogenesis. Front Neurosci 9: 114. 2015.

Williams, R., bacterial flora and pathogenesis in hepatic encephalopathy. Alimentary Pharmacology & Therapeutics, 2007. 25.

Cooper, å.J., et al., Cerebral ammonia metabolism in hyperammonemia rats. Journal of neurochemistry, 1985. 44(6): p. 1716-1723.

Rose, C.F., Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clinical Pharmacology & Therapeutics, 2012. 92(3): p. 321-331.

Dejong, C.H., et al., Cerebral cortex ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat. Journal of neurochemistry, 1992. 59(3): p. 1071-1079.

Lockwood, A.H., E.W. Yap, and W.-H. Wong, Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. Journal of Cerebral Blood Flow & Metabolism, 1991. 11(2): p. 337-341.

Kato, M., et al., Electron microscopic study of brain capillaries in cerebral edema from fulminant hepatic failure. Hepatology, 1992. 15(6): p. 1060-1066.

Sepehrinezhad, A., et al., Astrocyte swelling in hepatic encephalopathy: molecular perspective of cytotoxic edema. Metabolic brain disease, 2020. 35: p. 559-578.

Rungta, R.L., et al., The cellular mechanisms of neuronal swelling underlying cytotoxic edema. Cell, 2015. 161(3): p. 610-621.

Biller, A., et al., Exposure to 16 h of normobaric hypoxia induces ionic edema in the healthy brain. Nature Communications, 2021. 12(1): p. 5987.

Stokum, J.A., V. Gerzanich, and J.M. Simard, Molecular pathophysiology of cerebral edema. Journal of Cerebral Blood Flow & Metabolism, 2016. 36(3): p. 513-538.

Vorbrodt, A., et al., Ultrastructural observations on the transvascular route of protein removal in vasogenic brain edema. Acta neuropathologica, 1985. 66: p. 265-273.

Teixeira, M., F. Ribeiro Mde, and L. Gayotto, Chamone Dde a, Strauss e. Worse quality of life in volunteer blood donors with hepatitis C. Transfusion, 2006. 46: p. 278-283.

Dalby, F.R., et al., Understanding methane emission from stored animal manure: A review to guide model development. Journal of Environmental Quality, 2021. 50(4): p. 817-835.

Wilhelm, I., et al., Heterogeneity of the blood-brain barrier. Tissue Barriers, 2016. 4(1): p. e1143544.

Ng, F.C., et al., Microvascular Dysfunction in Blood-Brain Barrier Disruption and Hypoperfusion Within the Infarct Posttreatment Are Associated With Cerebral Edema. Stroke, 2022. 53(5): p. 1597-1605.

Chen, S., L. Shao, and L. Ma, Cerebral Edema Formation After Stroke: Emphasis on Blood-Brain Barrier and the Lymphatic Drainage System of the Brain. Front Cell Neurosci, 2021. 15: p. 716825.

Solar, P., et al., Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions. Front Cell Neurosci, 2022. 16: p. 922181.

Breviario, F., et al., Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. Arterioscler Thromb Vasc Biol, 1995. 15(8): p. 1229-39.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Martìn-Padura, I., et al., Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol, 1998. 142(1): p. 117-27.

Murakami, T., et al., Protein Kinase Cβ Phosphorylates Occludin Regulating Tight Junction Trafficking in Vascular Endothelial Growth Factor–Induced Permeability In Vivo. Diabetes, 2012. 61(6): p. 1573-1583

Stamatovic, S.M., et al., Junctional proteins of the blood-brain barrier: New insights into function and dysfunction. Tissue Barriers, 2016. 4(1): p. e1154641

Jiang, X., et al., Blood-brain barrier dysfunction and recovery after ischemic stroke. Progress in Neurobiology, 2018. 163-164: p. 144-171

Murakami, T., E.A. Felinski, and D.A. Antonetti, Occludin Phosphorylation and Ubiquitination Regulate Tight Junction Trafficking and Vascular Endothelial Growth Factor-induced Permeability *. Journal of Biological Chemistry, 2009. 284(31): p. 21036-21046.

Jiang, X., et al., Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog Neurobiol, 2018. 163-164: p. 144-171.

Liu, J., et al., Matrix Metalloproteinase-2-Mediated Occludin Degradation and Caveolin-1-Mediated Claudin-5 Redistribution Contribute to Blood–Brain Barrier Damage in Early Ischemic Stroke Stage. The Journal of Neuroscience, 2012. 32(9): p. 3044-3057.

Stamatovic, S.M., et al., Caveolae-mediated internalization of occludin and claudin-5 during CCL2-induced tight junction remodeling in brain endothelial cells. J Biol Chem, 2009. 284(28): p. 19053-66.

Shi, Y., et al., Rapid endothelial cytoskeletal reorganization enables early blood–brain barrier disruption and long-term ischaemic reperfusion brain injury. Nature Communications, 2016. 7(1): p. 10523.

Chen, Y., et al., Perihematomal edema after intracerebral hemorrhage: an update on pathogenesis, risk factors, and therapeutic advances. Frontiers in immunology, 2021. 12: p. 740632.

Strongin, A.Y., et al., Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem, 1995. 270(10): p. 5331-8.

Turner, R.J. and F.R. Sharp, Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke. Front Cell Neurosci, 2016. 10: p. 56.

Asahi, M., et al., Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood–Brain Barrier and White Matter Components after Cerebral Ischemia. The Journal of Neuroscience, 2001. 21(19): p. 7724-7732.

Qi, Z., et al., Zinc contributes to acute cerebral ischemia-induced blood-brain barrier disruption. Neurobiol Dis, 2016. 95: p. 12-21.

Akiyama, Y., et al., Susceptibility-weighted magnetic resonance imaging for the detection of cerebral microhemorrhage in patients with traumatic brain injury. Neurol Med Chir (Tokyo), 2009. 49(3): p. 97-9; discussion 99.

Kulkarni, P., et al., Evidence of early vasogenic edema following minor head impact that can be reduced with a vasopressin V1a receptor antagonist. Brain Res Bull, 2020. 165: p. 218-227.

Langfitt, T.W. and N.F. Kassell, Acute Brain Swelling in Neurosurgical Patients. Journal of Neurosurgery, 1966. 24(6): p. 975-983.

Cook, A.M., et al., Guidelines for the acute treatment of cerebral edema in neurocritical care patients. Neurocritical care, 2020. 32: p. 647-666.

Jha, R.M. and P.M. Kochanek, A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis? Current Neurology and Neuroscience Reports, 2018. 18(12): p. 105-105.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Chandra, V.V.R., et al., Cisternostomy versus Decompressive Craniectomy for the Management of Traumatic Brain Injury: A Randomized Controlled Trial. World Neurosurgery, 2022. 162: p. e58-e64

Kaufmann, A.M. and E.R. Cardoso, Aggravation of vasogenic cerebral edema by multiple-dose mannitol. Journal of Neurosurgery, 1992. 77(4): p. 584-589.

Kim, J.H., et al., Optimizing mannitol use in managing increased intracranial pressure: A comprehensive review of recent research and clinical experiences. Korean journal of neurotrauma, 2023. 19(2): p. 162.

Mishra, N.R., A. Agrawal, and R.R. Das, Hypertonic Saline vs. Mannitol in Management of Elevated Intracranial Pressure in Children: A Meta-Analysis. Indian Journal of Pediatrics, 2023. 90(9): p. 899-906.

Miyoshi, Y., et al., Effects of hypertonic saline versus mannitol in patients with traumatic brain injury in prehospital, emergency department, and intensive care unit settings: a systematic review and meta-analysis. Journal of Intensive Care, 2020. 8(1): p. 61-61.

Holden, D.N., et al., Hypertonic saline use in neurocritical care for treating cerebral edema: A review of optimal formulation, dosing, safety, administration and storage. American Journal of Health-System Pharmacy, 2023. 80(6): p. 331-342.

Hutchinson, P., I. Timofeev, and P. Kirkpatrick, Surgery for brain edema. Neurosurgical Focus, 2007. 22(5): p. 1-9.

French, L.A., THE USE OF STEROIDS IN THE TREATMENT OF CEREBRAL EDEMA*.

Rabinstein, A.A., Treatment of Cerebral Edema. The Neurologist, 2006. 12(2): p. 59-73

Todd, Michael M., J. Cutkomp, and Johnny E. Brian, Influence of Mannitol and Furosemide, Alone and in Combination, on Brain Water Content after Fluid Percussion Injury. Anesthesiology, 2006. 105(6): p. 1176-1181.

Jha, R.M., et al., Emerging therapeutic targets for cerebral edema. Expert opinion on therapeutic targets, 2021. 25(11): p. 917-938.

Papagianni, M., et al., Treatment with mannitol is associated with increased risk for in-hospital mortality in patients with acute ischemic stroke and cerebral edema. American Journal of Cardiovascular Drugs, 2018. 18: p. 397-403.

Sadan, O., et al., Correction to: Low-chloride-versus high-chloride-containing hypertonic solution for the treatment of subarachnoid hemorrhage–related complications: The ACETatE (A low ChloriE hyperTonic solution for brain Edema) randomized trial. Journal of Intensive Care, 2020. 8: p. 1-2.

Kalal, C.R., et al., Mannitol is comparable to hypertonic saline for raised intracranial pressure in acute liver failure (MAHAL Study): a randomized controlled trial. Digestive Diseases, 2022. 40(5): p. 607-615.

Luo, Z.-w., et al., Drug development in targeting ion channels for brain edema. Acta Pharmacologica Sinica, 2020. 41(10): p. 1272-1288.

Papadopoulos, M.C. and A.S. Verkman, Aquaporin-4 and brain edema. Pediatric Nephrology, 2007. 22(6): p. 778-784.

Li, Y., et al., Role of aquaporins in brain water transport and edema. Frontiers in Neuroscience, 2025. 19: p. 1518967.

Ji, C., et al., The role of glymphatic system in the cerebral edema formation after ischemic stroke. Experimental Neurology, 2021. 340: p. 113685.

Ju, Z., et al., Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years. Acta Pharmaceutica Sinica B, 2022. 12(6): p. 2790-2807.

Shi, S. and U. Klotz, Clinical use and pharmacological properties of selective COX-2 inhibitors. European Journal of Clinical Pharmacology, 2008. 64(3): p. 233-252.

Sun, T., et al., Deferoxamine in intracerebral hemorrhage: Systematic review and meta-analysis. Clinical Neurology and Neurosurgery, 2023. 227: p. 107634-107634.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Yu, Y., et al., The Clinical Effect of Deferoxamine Mesylate on Edema after Intracerebral Hemorrhage. PLOS ONE, 2015. 10(4): p. e0122371-e0122371.

Halstead, M.R. and R.G. Geocadin, The Medical Management of Cerebral Edema: Past, Present, and Future Therapies. Neurotherapeutics, 2019. 16(4): p. 1133-1148.

Marmarou, A., Pathophysiology of traumatic brain edema: current concepts, iBrain Edema XII. 2003, Springer Vienna: Vienna. p. 7-10.

Y. Deng, Y., et al., Progress in drug treatment of cerebral edema. Mini reviews in medicinal chemistry, 2016. 16(11): p. 917-925.

Jiang, C., et al., Molecular, pathological, clinical, and therapeutic aspects of perihematomal edema in different stages of intracerebral hemorrhage. Oxidative Medicine and Cellular Longevity, 2022. 2022(1): p. 3948921.

Baig, M., et al., Prevalence of myocardial edema with t2 mapping in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2021. 77(18_Supplement_1): p. 1303-1303.

Deshmukh, K.P., et al., Recent technological developments in the diagnosis and treatment of cerebral edema. Advanced NanoBiomed Research, 2021. 1(11): p. 2100001